Skip to content

miRagen tops earnings, revenue views

August 13, 2017

miRagen Therapeutics (NASDAQ: MGEN) reported Q2 EPS of ($0.34), $0.13 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $718 thousand versus the consensus estimate of $500 thousand.

  • Revenue decreased to $0.7 million during the second quarter of 2017, from $1.1 million during the same period in 2016. The $0.4 million decrease was due primarily to decreases in license fee and development related revenue under the Company’s collaboration agreement with Servier.
  • Research and development expenses increased to $5.5 million during the second quarter of 2017, from $3.4 million during the same period in 2016. The $2.1 million increase was due primarily to a $1.3 million increase in outsourced manufacturing expenses, a $0.3 million increase in clinical trial expense, and a $0.8 million increase in personnel costs, including share based compensation. These increases were partially offset by a $0.3 million decrease in outsourced preclinical costs.
  • General and administrative expenses increased to $2.6 million during the second quarter of 2017, from $1.2 million during the same period in 2016. The $1.4 million increase was due primarily to a $0.8 million increase in legal and other professional fees and expenses related primarily to increased costs associated with being a public company and increased personnel costs of $0.4 million, including share based compensation.

http://bit.ly/2fCJ04B

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: